Search results
BMS’ Opdivo-Yervoy treatment improves survival in hepatocellular carcinoma trial
Clinical Trials Arena via Yahoo Finance· 20 hours agoBristol Myers Squibb (BMS) has announced findings from the Phase III CheckMate -9DW trial where ...
Bristol Myers (BMY) Reports Positive Data on Breyanzi, Opdivo (Revised)
Zacks via Yahoo Finance· 1 day agoBristol Myers (BMY) announces positive data from three studies evaluating CAR T cell therapy...
Bristol Myers Squibb Announces Phase 3 Results Of Opdivo/Yervoy Combo In Liver Cancer Patients -...
Benzinga· 2 days agoOpdivo plus Yervoy combo shows significant survival benefits and higher response rates vs....
Pre-surgery treatment with Bristol Myers combination therapy leads to better skin cancer outcomes
Reuters· 4 days ago, opens new tab immunotherapies Opdivo and Yervoy prior to surgery for patients whose skin cancer...
ASCO: Early Purple data gain ground in metastatic pancreatic cancer
FierceBiotech· 5 days agoPurple’s anti-CEACAM1 antibody, dubbed CM24, was offered to previously treated patients in...
Lack of insurance keeps many Americans from best cancer meds
Medical Xpress· 3 days agoThe study was led by ACS researcher Dr. Jingxuan Zhao. ICIs include such blockbuster cancer...
Neoadjuvant Strategy Establishes Standard of Care for Resectable Stage III Melanoma
MedPage Today· 2 days agoCombination neoadjuvant immunotherapy for resectable melanoma reduced recurrence and other clinical...
Why US Drug Giant Bristol Myers Squibb Stock Trading Up On Monday - Bristol-Myers Squibb (NYSE:BMY)
Benzinga· 3 days agoBristol Myers Squibb & Co BMY announced on Saturday (June 1) results from the Phase 3 KRYSTAL-12...
ASCO24: Tagrisso in the spotlight, Caribou’s adjustment and Lilly’s KRAS competitor
BioPharma Dive via Yahoo Finance· 3 days agoA study by Bristol Myers Squibb showed that before surgery, or “neoadjuvant,” treatment with Opdivo...
Blood Purification Medical Devices Revolutionizing the Future of Health from Cancer to COVID
Digital Journal· 3 days agoAethlon Medical, Inc. (NASDAQ: AEMD), with a long history of development for its patented Hemopurifier® blood purification device, just released an update on its planned phase 1 safety, feasibility ...